Show simple item record

dc.contributor.authorViswanath, Pavithra
dc.contributor.authorRadoul, Marina
dc.contributor.authorIzquierdo-Garcia, Jose L. 
dc.contributor.authorLuchman, Hema Artee
dc.contributor.authorGregory Cairncross, J
dc.contributor.authorPieper, Russell O
dc.contributor.authorPhillips, Joanna J
dc.contributor.authorRonen, Sabrina M
dc.date.accessioned2019-02-21T10:18:49Z
dc.date.available2019-02-21T10:18:49Z
dc.date.issued2018
dc.identifier.citationCancer Metab. 2018; 6:3es_ES
dc.identifier.issn2049-3002es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7206
dc.description.abstractBackground: Magnetic resonance spectroscopy (MRS) studies have identified elevated levels of the phospholipid precursor phosphocholine (PC) and phosphoethanolamine (PE) as metabolic hallmarks of cancer. Unusually, however, PC and PE levels are reduced in mutant isocitrate dehydrogenase 1 (IDHmut) gliomas that produce the oncometabolite 2-hydroxyglutarate (2-HG) relative to wild-type IDH1 (IDHwt) gliomas. The goal of this study was to determine the molecular mechanism underlying this unusual metabolic reprogramming in IDHmut gliomas. Methods: Steady-state PC and PE were quantified using 31P-MRS. To quantify de novo PC and PE synthesis, we used 13C-MRS and measured flux to 13C-PC and 13C-PE in cells incubated with [1,2-13C]-choline and [1,2-13C]-ethanolamine. The activities of choline kinase (CK) and ethanolamine kinase (EK), the enzymes responsible for PC and PE synthesis, were quantified using 31P-MR-based assays. To interrogate the role of 2-HG, we examined IDHwt cells incubated with 2-HG and, conversely, IDHmut cells treated with the IDHmut inhibitor AGI-5198. To examine the role of hypoxia-inducible factor 1-α (HIF-1α), we silenced HIF-1α using RNA interference. To confirm our findings in vivo and in the clinic, we studied IDHwt and IDHmut orthotopic tumor xenografts and glioma patient biopsies. Results: De novo synthesis of PC and PE was reduced in IDHmut cells relative to IDHwt. Concomitantly, CK activity and EK activity were reduced in IDHmut cells. Pharmacological manipulation of 2-HG levels established that 2-HG was responsible for reduced CK activity, EK activity, PC and PE. 2-HG has previously been reported to stabilize levels of HIF-1α, a known regulator of CK activity. Silencing HIF-1α in IDHmut cells restored CK activity, EK activity, PC and PE to IDHwt levels. Our findings were recapitulated in IDHmut orthotopic tumor xenografts and, most importantly, in IDHmut patient biopsies, validating our findings in vivo and in the clinic. Conclusions: This study identifies, to our knowledge for the first time, a direct role for 2-HG in the downregulation of CK and EK activity, and thereby, PC and PE synthesis in IDHmut gliomas. These results highlight the unusual reprogramming of phospholipid metabolism in IDHmut gliomas and have implications for the identification of MRS-detectable metabolic biomarkers associated with 2-HG status.es_ES
dc.description.sponsorshipThis work was supported by the following grants: NIH R01CA172845 (SMR), NIH R01CA197254 (SMR), NIH R01CA154915 (SMR), FP7/2007-2013 REA600396 (JLI), SAF2014-59118-JIN (JLI), UCSF Brain Tumor Loglio Collective (SMR, ROP, JJP), NICO (SMR), UCSF Brain Tumor Research Center SPORE Tissue Core (P50CA97257) and UCSF Brain Tumor Research Center SPORE Career Development Grant (P50CA97257 to PV).es_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject2-Hydroxyglutaratees_ES
dc.subjectBrain tumorses_ES
dc.subjectCholine kinasees_ES
dc.subjectEthanolamine kinasees_ES
dc.subjectHIF-1αes_ES
dc.subjectIDH1 mutationes_ES
dc.subjectMagnetic resonance spectroscopyes_ES
dc.subjectMetabolic reprogramminges_ES
dc.subjectPhosphocholinees_ES
dc.subjectPhosphoethanolaminees_ES
dc.titleMutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manneres_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29619216es_ES
dc.format.volume6es_ES
dc.format.number1es_ES
dc.format.page3es_ES
dc.identifier.doi10.1186/s40170-018-0178-3es_ES
dc.contributor.funderNational Institutes of Health (Estados Unidos) 
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1186/s40170-018-0178-3es_ES
dc.identifier.journalCancer & metabolismes_ES
dc.repisalud.orgCNICCNIC::Unidades técnicases_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional